Remission in rheumatoid arthritis: is it all the same?

References

• Peluso G, Michelutti A, Bosello S, et al. Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis 2011;70(1):172-5
   PubMed Web of Science ®Google Scholar
• Katchamart W, Johnson S, Lin HJ, et al. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken) 2010;62(8):1128-43
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372(9636):375-82
   PubMed Web of Science ®Google Scholar
• Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69(9):1636-42
   PubMed Web of Science ®Google Scholar
• Saleem B, Brown AK, Keen H, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. Arthritis Rheum 2009;60(7):1915-22
   PubMed Web of Science ®Google Scholar
• Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006;24(6 Suppl 43):S-33-6
   Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2013 update. Ann Rheum Dis 2014;73(3):492-509
   PubMed Web of Science ®Google Scholar
• Westhovens R, Verschueren P. Rheumatoid arthritis: defining remission in patients with RA in clinical practice. Nat Rev Rheumatol 2012;8(8):445-7
   PubMed Web of Science ®Google Scholar
• Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58(10):2958-67
   PubMed Web of Science ®Google Scholar
• Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54(12):3761-73
   PubMed Web of Science ®Google Scholar
• Saleem B, Brown AK, Keen H, et al. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis 2011;70(5):792-8
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39(1):28-33
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin Exp Rheumatol 2013;31(4 Suppl 78):S19-21
   PubMed Web of Science ®Google Scholar
• Nam JL, Villeneuve E, Hensor EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis 2014;73(6):1027-36
   PubMed Web of Science ®Google Scholar
• Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381(9870):918-29
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74(2):389-95
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69(7):1286-91
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2015;74(5):843-50
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hirata S, Saleem B, et al. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013;31(4 Suppl 78):S22-7
   PubMed Web of Science ®Google Scholar
• Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7(4):R784-95
   PubMed Web of Science ®Google Scholar
• Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24(10):1308-15
   PubMed Web of Science ®Google Scholar
• Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32(10):2016-24
   PubMed Web of Science ®Google Scholar
• Bykerk VP, Massarotti EM. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford) 2012;51(Suppl 6):vi16-20
   PubMedGoogle Scholar
• Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36(6):729-40
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011;70(10):1815-21
   PubMed Web of Science ®Google Scholar
• Bentley MJ, Greenberg JD, Reed GW. A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. J Rheumatol 2010;37(8):1607-14
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van ’t Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49(11):916-20
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38(1):44-8
   PubMed Web of Science ®Google Scholar
• Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52(9):2625-36
   PubMed Web of Science ®Google Scholar
• Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology (Oxford) 2007;46(6):975-9
   PubMed Web of Science ®Google Scholar
• Makinen H, Kautiainen H, Hannonen P, et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64(10):1410-13
   PubMed Web of Science ®Google Scholar
• Wakefield RJ, D’Agostino MA, Naredo E, et al. After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? Post Grad Med J 2012;88(1042):482-6
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42(2):244-57
   PubMed Web of Science ®Google Scholar
• Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7(4):R796-806
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005;32(12):2410-15
   PubMed Web of Science ®Google Scholar
• Pincus T, Swearingen CJ, Bergman M, et al. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 2008;35(11):2136-47
   PubMed Web of Science ®Google Scholar
• Leeb BF, Haindl PM, Maktari A, et al. Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI. J Rheumatol 2008;35(7):1294-9
   PubMed Web of Science ®Google Scholar
• Rintelen B, Sautner J, Haindl P, et al. Remission in rheumatoid arthritis: a comparison of the 2 newly proposed ACR/EULAR remission criteria with the rheumatoid arthritis disease activity index-5, a patient self-report disease activity index. J Rheumatol 2013;40(4):394-400
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006;54(9):2784-92
   PubMed Web of Science ®Google Scholar
• Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67(7):745-53
   PubMed Web of Science ®Google Scholar
• Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008;59(10):1371-7
   PubMed Web of Science ®Google Scholar
• Wechalekar MD, Lester S, Proudman SM, et al. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. Arthritis Rheum 2012;64(5):1316-22
   PubMed Web of Science ®Google Scholar
• Vermeer M, Kuper HH, van der Bijl AE, et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford) 2012;51(6):1076-80
   PubMed Web of Science ®Google Scholar
• Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 2012;71(10):1702-5
   PubMed Web of Science ®Google Scholar
• Masri KR, Shaver TS, Shahouri SH, et al. Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice. J Rheumatol 2012;39(6):1139-45
   PubMed Web of Science ®Google Scholar
• Kuriya B, Sun Y, Boire G, et al. Remission in early rheumatoid arthritis – a comparison of new ACR/EULAR remission criteria to established criteria. J Rheumatol 2012;39(6):1155-8
   PubMed Web of Science ®Google Scholar
• Emery P, Kavanaugh A, Bao Y, et al. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69(4):631-7
   PubMed Web of Science ®Google Scholar
• van Tuyl LH, Felson DT, Wells G, et al. Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2010;62(1):108-17
   PubMed Web of Science ®Google Scholar
• van Tuyl LH, Hewlett S, Sadlonova M, et al. The patient perspective on remission in rheumatoid arthritis: ’You’ve got limits, but you’re back to being you again’. Ann Rheum Dis 2015;74(6):1004-10
   PubMed Web of Science ®Google Scholar
• Esselens G, Westhovens R, Verschueren P. Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskelet Care 2009;7(1):1-16
   PubMedGoogle Scholar
• Haavardsholm EA, Lie E, Lillegraven S. Should modern imaging be part of remission criteria in rheumatoid arthritis? Best Pract Res Clin Rheumatol 2012;26(6):767-85
   PubMed Web of Science ®Google Scholar
• Scire CA, Montecucco C, Codullo V, et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford) 2009;48(9):1092-7
   PubMed Web of Science ®Google Scholar
• Saleem B, Brown AK, Quinn M, et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis 2012;71(8):1316-21
   PubMed Web of Science ®Google Scholar
• Yoshimi R, Hama M, Takase K, et al. Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis. Mod Rheumatol 2013;23(3):456-65
   PubMed Web of Science ®Google Scholar
• Fukae J, Isobe M, Kitano A, et al. Structural deterioration of finger joints with ultrasonographic synovitis in rheumatoid arthritis patients with clinical low disease activity. Rheumatology (Oxford) 2014;53(9):1608-12
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Suzuki T, Nakashima Y, et al. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. Rheumatology (Oxford) 2014;53(3):562-9
   PubMed Web of Science ®Google Scholar
• Molenaar ET, Voskuyl AE, Dinant HJ, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50(1):36-42
   PubMed Web of Science ®Google Scholar
• Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013;72(6):804-14
   PubMed Web of Science ®Google Scholar
• Axelsen MB, Eshed I, Duer-Jensen A, et al. Whole-body MRI assessment of disease activity and structural damage in rheumatoid arthritis: first step towards an MRI joint count. Rheumatology (Oxford) 2014;53(5):845-53
   PubMed Web of Science ®Google Scholar
• Gandjbakhch F, Haavardsholm EA, Conaghan PG, et al. Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a follow-up MRI study of 254 patients in clinical remission or low disease activity. J Rheumatol 2014;41(2):398-406
   PubMed Web of Science ®Google Scholar
• Kubota K, Ito K, Morooka M, et al. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci 2011;1228:29-38
   PubMed Web of Science ®Google Scholar
• Kubota K, Ito K, Morooka M, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med 2009;23(9):783-91
   PubMed Web of Science ®Google Scholar
• Cope AP. T cells in rheumatoid arthritis. Arthritis Res Ther 2008;10(Suppl 1):S1
   PubMed Web of Science ®Google Scholar
• Ponchel F, Morgan AW, Bingham SJ, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002;100(13):4550-6
   PubMed Web of Science ®Google Scholar
• Gullick NJ, Evans HG, Church LD, et al. Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PLoS One 2010;5:9
   PubMed Web of Science ®Google Scholar
• Ramirez J, Ruiz-Esquide V, Pomes I, et al. Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers. Arthritis Res Ther 2014;16(1):R5
   PubMed Web of Science ®Google Scholar
• Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8(4):e60635
   PubMed Web of Science ®Google Scholar
• Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012;64(12):1794-803
   PubMed Web of Science ®Google Scholar
• Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71(10):1692-7
   PubMed Web of Science ®Google Scholar
• Hirata S, Dirven L, Shen Y, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013;52(7):1202-7
   PubMed Web of Science ®Google Scholar
• Li W, Sasso EH, Emerling D, et al. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin 2013;29(1):85-92
   PubMed Web of Science ®Google Scholar
• Haney DJ, Cavet G, Durez P, et al. Correlation Of A Multi-biomarker disease activity response assessment to disease activity score 28 (C-reactive protein) response assessment and omeract ramris scores in a placebo-controlled rheumatoid arthritis clinical trial with abatacept (ASSET). Arthritis Rheum 2012;64(Suppl 10):2159
   Google Scholar
• Krabbe S, Bolce RJ, Brahe CH, et al. Validation of a multi-biomarker disease activity score in rheumatoid arthritis in relation to imaging inflammation and damage. Ann Rheum Dis 2014;73(Suppl 2):396
   PubMedGoogle Scholar
• van der Helm-van Mil AH, Knevel R, Cavet G, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford) 2013;52(5):839-46
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, van der Heijde D, Boers M, et al. The Sharp/van der Heijde method out-performed the Larsen/Scott method on the individual patient level in assessing radiographs in early rheumatoid arthritis. J Clin Epidemiol 2004;57(5):502-12
   PubMed Web of Science ®Google Scholar
• Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis 2015;74(6):1102-9
   PubMed Web of Science ®Google Scholar
• Hirata S, Li W, Defranoux N, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Mod Rheumatol 2015;25(3):344-9
   PubMed Web of Science ®Google Scholar
• Segurado OG, Sasso EH. Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 2014;32(5 Suppl 85):S-29-34
   Web of Science ®Google Scholar
• Anandarajah A, Thiele R, Giampoli E, et al. Patients with rheumatoid arthritis in clinical remission manifest persistent joint inflammation on histology and imaging studies. J Rheumatol 2014;41(11):2153-60
   PubMed Web of Science ®Google Scholar
• Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43(10):1252-5
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63(3):573-86
   PubMed Web of Science ®Google Scholar